Amneal Seeks FDA Approval For Its Parkinson's Candidate

  • Amneal Pharmaceuticals Inc AMRX submitted a marketing application to the FDA seeking approval for IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson's disease.
  • The submission is based on results from the pivotal Phase 3 RISE-PD clinical trial demonstrating more "Good On" time than immediate-release CD/LD.
  • Related Content: Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022.
  • IPX203 was dosed on average three times per day, and immediate-release CD/LD was dosed on average five times per day. The trial also showed that subjects on IPX203 demonstrated significantly less "Off" time compared with immediate-release CD/LD. 
  • A post-hoc analysis showed that IPX203 provided 1.55 more hours of "Good On" time per dose versus immediate-release CD/LD, representing a 70% per dose increase.
  • Price Action: AMRX shares are up 1.61% at $2.21 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!